InDex Pharmaceuticals AB

InDex Pharmaceuticals develops Kappaproct – a completely new type of drug that can help patients with moderate to severe ulcerative colitis back to a normal life.

Kappaproct is a first in class treatment that provides a local anti-inflammatory effect. Kappaproct has very limited systemic absorption. This gives the drug a favorable safety profile, in sharp contrast to many approved treatments. InDex has also developed a platform of patent protected substances, so called DNA based immunomodulatory sequences (DIMS), with the potential to be used in treatment of various immunological diseases.


Kategorier: Pharma

Gå till InDex Pharmaceuticals ABs hemsida